Vaccines Video Recap—November 14, 2025

This biweekly video recap highlights early-phase immunogenicity and safety signals, real-world effectiveness data, trial launches, and a regional manufacturing milestone.

🎯 Watch Our Video Summary Capturing Vaccines News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 31 October–6 November 2025
Week 7–13 November 2025

📚 See the full Vaccines archive on our research hub page.

Transcript

Welcome to this week’s edition of Vaccine Research Updates, covering the latest breakthroughs. Brought to you by LucidQuest.

GC Biopharma’s Phase 2 trial results for BARYTHRAX, the world’s first recombinant anthrax vaccine, demonstrate strong immune responses and a favorable safety profile. Developed in collaboration with the Korea Disease Control and Prevention Agency, this vaccine could enhance global anthrax protection.

Valneva’s Phase 1 trial results for its second-generation Zika vaccine, VLA1601, show promising immune responses and safety. The double-adjuvanted formulation yielded the best immune response, positioning VLA1601 as a potential breakthrough in Zika prevention.

CastleVax has initiated a Phase 2 study for CVAX-01, an intranasal COVID-19 vaccine designed to offer enhanced protection by generating both systemic and mucosal immunity against SARS-CoV-2.

Transgene’s neoantigen-based cancer vaccine, TG4050, demonstrated strong CD8+ T cell responses in Phase 1 trials, showing potential to prevent cancer relapse, especially in patients with head and neck squamous cell carcinoma.

Akeso has dosed its first patient in a Phase 1 trial of its personalized mRNA vaccine, AK154, designed to treat pancreatic cancer by targeting tumor-specific neoantigens.

Anixa Biosciences has advanced its breast cancer vaccine, which targets the α-Lactalbumin protein, to Phase 2 after showing promising Phase 1 results. This vaccine could offer therapeutic and preventive benefits for breast cancer patients.

A real-world study of the RTS,S malaria vaccine demonstrated a 30% reduction in malaria incidence and a 58% reduction in severe malaria, reinforcing its effectiveness in real-world settings.

South Africa has begun clinical trials for its first fully manufactured oral cholera vaccine, marking a major milestone in enhancing Africa’s vaccine production capabilities.

Stay ahead in vaccine research! Like, share, and subscribe for weekly updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It Matters

Anthrax Vaccine: BARYTHRAX’s successful Phase 2 results offer a promising solution to enhancing protection against anthrax, particularly in the context of bioterrorism preparedness.
Zika Vaccine: Valneva’s second-generation Zika vaccine shows significant promise in preventing the disease, a growing public health challenge as climate change spreads mosquito habitats.
COVID-19 Vaccine: CastleVax’s intranasal vaccine could revolutionize COVID-19 prevention by providing mucosal immunity, which is critical for blocking viral entry at the site of infection.
Cancer Immunotherapy: Transgene’s TG4050 shows great potential in reducing cancer relapse through personalized immune responses, making it a valuable addition to cancer immunotherapy.
Pancreatic Cancer Vaccine: AK154 could offer new hope for pancreatic cancer patients by targeting specific tumor mutations with mRNA technology.
Breast Cancer Vaccine: Anixa’s vaccine offers a novel therapeutic approach to prevent and treat breast cancer, a critical area of need in oncology.
Malaria Control: The RTS,S vaccine’s proven effectiveness in real-world settings supports its ongoing use and potential for scaling up malaria prevention globally.
Cholera Vaccine: South Africa’s milestone in producing a fully manufactured cholera vaccine marks a major step forward for local vaccine production and health security across the continent.

🗓️ Explore weekly details and sources

Week 31 October–6 November 2025
Week 7–13 November 2025

📚 See the full Vaccines archive on our research hub page.

FAQ

What are the results of the BARYTHRAX Phase 2 trial?

The BARYTHRAX vaccine demonstrated strong immunogenicity, eliciting protective antibody levels, and a favorable safety profile in a Phase 2 trial, positioning it as a promising solution for anthrax protection.

What’s the significance of Valneva’s Zika vaccine?

Valneva’s second-generation Zika vaccine showed improved immune responses, particularly with double-adjuvanted formulations, making it a promising candidate for addressing the growing Zika virus threat.

How does CastleVax’s intranasal COVID-19 vaccine work?

CastleVax’s CVAX-01 is designed to generate both systemic and mucosal immunity, offering a potential solution to block SARS-CoV-2 infection and transmission, especially in high-risk populations.

What data does Transgene’s TG4050 present for cancer treatment?

TG4050 demonstrated the ability to induce potent and long-lasting CD8+ T cell responses, potentially reducing cancer relapse and improving long-term patient outcomes.

What are the implications of Anixa Biosciences advancing its breast cancer vaccine?

Anixa’s vaccine targeting the α-Lactalbumin protein has shown promise in Phase 1 trials and could offer both therapeutic and preventive benefits for breast cancer patients.

Entities / Keywords

GC Biopharma; BARYTHRAX; anthrax vaccine
Valneva; Zika vaccine
CastleVax; CVAX-01; COVID-19 vaccine
Transgene; TG4050; cancer relapse
Akeso; AK154; personalized mRNA vaccine
Anixa Biosciences; breast cancer vaccine
RTS,S; malaria vaccine
South Africa; cholera vaccine